Table 2.
PsA patients’ characteristics. The patients were stratified in non-D2T and D2T
| PsA patients | |||
|---|---|---|---|
| Overall, n = 106 | |||
| Non-D2T n = 70 (66.1%) |
D2T n = 36 (33.9%) |
p value | |
| Demographic, physical characteristics | |||
| Sex (male), n (%) | 47/70 (67.1) | 21/36 (58.3) | 0.370 |
| Age, median (IQR) | 58.5 (46.5–67.7) | 58 (52–67) | 0.657 |
| Weight (kg), median (IQR) | 73 (65.5–84) | 79 (70–83) | 0.235 |
| Height (cm), median (IQR) | 1.69 (1.6–1.7) | 1.68 (1.6–1.7) | 0.298 |
| BMI (kg/h2), median (IQR) | 25.7 (22.8–29.0) | 27.7 (24.5–30.6) | 0.032 |
| Clinical PsA characteristics | |||
| Disease duration (months), median (IQR) | 67 (24–156) | 81 (30–120) | 0.668 |
| PsA subset | |||
| Axial, n (%) | 7/63 (11.1) | 1/34 (2.9) | 0.163 |
| Monoarticular, n (%) | 5/63 (7.9) | 0/34 (0) | |
| Oligoarticular, n (%) | 21/63 (33.3) | 11/34 (32.3) | |
| Polyarticular, n (%) | 21/63 (33.3) | 19/34 (55.8) | |
| Enthesitics, n (%) | 8/63 (12.7) | 3/34 (8.8) | |
| Prevalent DIP involvement, n (%) | 1/63 (1.6) | 0/34 (0) | |
| Axial involvement, n (%) | 7/63 (11.1) | 1/34 (2.9) | |
| Peripheral involvement, n (%) | 56/63 (88.9) | 33/34 (97.1) | 0.162 |
| Uveitis present or past, n (%) | 3/69 (4.3) | 2/36 (5.5) | 0.537 |
| Crohn’s disease, n (%) | 0/69 (0) | 1/36 (2.7) | 0.342 |
| Ulcerative colitis, n (%) | 0/69 (0) | 0/36 (0) | 1 |
| Psoriasis at the visit moment, n (%) | 35/65 (53.8) | 27/32 (84.3) | < 0.001 |
| BSA, median (IQR) | 0.25 (0–1.2) | 1 (1–4.2) | < 0.01 |
| PASS yes, n (%) | 66/70 (94.2) | 8 (22.2) | < 0.01 |
| Patient Global Assessment, median (IQR) | 2 (1–5) | 6 (5–8) | < 0.01 |
| Patient pain on VAS, median (IQR) | 2.5 (1–5) | 7 (5–8) | < 0.01 |
| Dactylitis, n (%) | |||
| Past or present | 18/62 (29) | 11/36 (30.5) | 0.873 |
| CRP (mg/dl), median (IQR) | 0.2 (0.2–0.4) | 0.2 (0.2–0.6) | 0.288 |
| DAPSA, median (IQR) | 7.1 (3–12) | 17.2 (12.3–26) | < 0.01 |
| PsA function and impact | |||
| PsAID, median (IQR) | 1.91 (0.8–4.7) | 5.30 (2.9–8.2) | < 0.001 |
| HAQ-DI, median (IQR) | 0.25 (0–0.6) | 1 (0.5–1.4) | < 0.001 |
| Comorbidities indices | |||
| CCI, median (IQR) | 0 (0–0) | 0 (0–1) | 0.179 |
| FCI, median (IQR) | 0 (0–1) | 1 (0–1) | 0.021 |
| CCI ≥ 1, n (%) | 14/96 (20.3) | 11/36 (30.6) | 0.241 |
| FCI ≥ 1, n (%) | 25/69 (36.2) | 21/36 (58.3) | 0.030 |
| Presence of fibromyalgia, n (%) | 5/69 (7.2) | 8/36 (22.9) | 0.022 |
Bold values represent those statistically significant